Drug Target Review

JANUARY 15, 2024

Could you provide insights into the driving factors behind exploring novel treatments for cancer types? Based on this rationale we selected skin cancer, triple-negative breast cancer, and head and neck cancers as our initial indications for our Phase 1 trials. What aspects prompted this research direction?

Treatment 105

Treatment Immune Response Clinical Trials Therapies 105

Drug Discovery World

SEPTEMBER 21, 2022

Otsuka Pharmaceutical’s Lupkynis (voclosporin) is the first oral treatment to be approved in Europe for the treatment of active lupus nephritis (LN) in adult patients. The combination treatment for this indication was approved by the US Food and Drug Administration in 2021 and gained a positive opinion from the CHMP earlier this year.

Treatment 130

Treatment Licensing Licensing Pharmaceuticals 130

Drug Discovery World

MAY 8, 2024

The ORCA-V1 trial was led by Achieve Life Sciences, and co-led by an investigator from Massachusetts General Hospital. “No In their previous clinical trial, the research team found that cytisinicline helped people to quit smoking traditional cigarettes. “The For cytisinicline treatment compared to placebo, 31.8% versus 15.1%

Clinical Trials 182

Clinical Trials Compliance Trials Drugs 182

Drug Discovery World

APRIL 18, 2024

First results from the EAGLE-1 Phase III trial for gepotidacin show that two oral doses of the antibiotic displayed superior success rates (92.6%) when compared to the combination treatment of ceftriaxone and oral azithromycin, which saw a 91.2% The imperative for innovative treatments has never been clearer. success rate.

Trials 130

Trials DNA Treatment Regulations 130

Drug Discovery World

FEBRUARY 21, 2024

In October 2023, pharmaceutical company NKGen Biotech released data from its Phase I clinical trial on the use of its investigational natural killer therapy, SNK01, to treat patients with Alzheimer’s disease. RA: What are the clinical benefits of using the patient’s own cells as a treatment? What will be the goals from this study?

Therapies 306

Therapies Treatment Trials Disease 306

The Pharma Data

JANUARY 27, 2021

COVID-19 Antibody Treatments Exceed Expectations in Early Trials. 27, 2021 — Promising new data on two antibody cocktails suggest these therapies can keep COVID-19 patients out of the hospital and even prevent illness altogether in some people. © 2021 HealthDay. Posted: January 2021. Professional.

Treatment 52

Treatment Trials Hospitals Virus 52

Drug Discovery World

JULY 30, 2024

To reach their conclusions, the team emulated seven target trials among eligible patients with comorbid T2DM and TUD by comparing the new use of semaglutide versus seven other anti-diabetes medications. The authors have called for clinical trials to evaluate semaglutide’s potential as a TUD treatment.

Trials 130

Trials Clinical Trials Treatment International 130

Drug Discovery World

JULY 31, 2024

million grant from the Medical Research Future Fund’s (MRFF) National Critical Research Infrastructure programme, the new hub will provide the local research community with vaccines that match the specific treatment needs of each patient. Backed by a $3.3

Vaccine 147

Vaccine Clinical Trials Hospitals Treatment 147

Drug Discovery World

SEPTEMBER 17, 2024

Where do you work, and can you tell us what you’re working on at the moment?  I work at Poolbeg Pharma, where we are developing novel treatments for diseases with unmet medical needs and large addressable markets, with programmes in oncology, infectious diseases and endocrinology.

Research 221

Research Clinical Trials Disease Trials 221

The Pharma Data

JANUARY 4, 2021

5, 2021 07:00 UTC. February 12, 2021. March 25, 2021. 2021 First Quarter Financial Update. April 21, 2021. 2021 Second Quarter Financial Update. July 21, 2021.

Treatment 52

Treatment Trials Clinical Trials Disease 52

Drug Discovery World

MARCH 1, 2024

Pepaxto associated with increased risk of death The FDA is alerting patients and health care professionals that a clinical trial (OCEAN, Study OP-103) evaluating Pepaxto with dexamethasone showed an increased risk of death. The FDA has now suspended enrolment in all ongoing Pepaxto clinical trials.

FDA 130

FDA Clinical Trials FDA Approval Trials 130

The Pharma Data

JULY 29, 2021

econd Quarter 2021 Product Sales Increased 21% Year-Over-Year Primarily Driven by Veklury. Nasdaq: GILD) announced today its results of operations for the second quarter 2021. “We The series of promising pipeline updates included the data from the landmark ZUMA-7 study for the treatment of second-line large B-cell lymphoma.

Science 52

Science Production Treatment FDA 52

Advarra

JUNE 20, 2023

Additionally, in 2021, a literature review estimated the average capitalized research and development (R&D) costs per new cancer medicine at between $944 million and $4.54 Innovation Organizations conducting oncology clinical trials face challenges distinct from the rest of the research community.

Trials 52

Trials Clinical Trials FDA Approval Animal Testing 52

The Pharma Data

DECEMBER 20, 2020

Followed by Russia , Indonesia, and Korea, the second phase of the COVID-19 clinical trial was approved in Italy on Friday, December 18, 2020. Currently, it is smoothly progressing with the approval for Phase 2 clinical trials in four countries, and it is expected to see the results sequentially starting as early as the third quarter of 2021.

Clinical Trials 40

Clinical Trials Treatment Trials Hospitals 40

The Pharma Data

MAY 17, 2021

The agency noted that master protocols can save drugmakers time and money in study startup and can accelerate drug development by evaluating multiple drugs at the same time and maximizing the amount of information gained during research, compared to stand-alone trials.

FDA 52

FDA Trials Therapies Treatment 52

The Pharma Data

JANUARY 10, 2021

The UK’s National Health Service (NHS) will begin treating adult COVID-19 patients in intensive care with Roche’s and Sanofi’s arthritis medications following positive trial results that showed the drugs were highly effective when given early enough. Read the ICL trial results here: bit.ly/3hWEGJi. James Miessler. Source link.

Treatment 52

Treatment Government Hospitals Drugs 52

The Pharma Data

NOVEMBER 2, 2020

ONWARD Projected to be Fully Enrolled During Q2 2021. NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today provided an update on its landmark ONWARD Phase 3 pivotal trial. Data readout is expected in Q4 2021 or earlier.

Trials 52

Trials Treatment Pharmaceuticals Clinical Trials 52

The Pharma Data

AUGUST 3, 2021

Revenue in the second quarter of 2021 increased 23 percent, driven by volume growth of 22 percent. – Revenue from all key products grew in the quarter and 2021 year-to-date. . – Revenue from all key products grew in the quarter and 2021 year-to-date. – 2021 EPS guidance updated to be in the range of $6.73

Production 52

Production Marketing Research Government 52

The Pharma Data

JANUARY 12, 2021

13, 2021 /PRNewswire/ — Adastra Pharmaceuticals, Inc., 13, 2021 /PRNewswire/ — Adastra Pharmaceuticals, Inc., The trial investigated the safety and efficacy of ZTR, in combination with temozolomide (TMZ), in patients with recurrent high-grade gliomas. NCI’s Principal Investigator of the 17-C-0009 trial.

Clinical Trials 52

Clinical Trials Trials Treatment Pharmaceuticals 52

The Pharma Data

JANUARY 17, 2021

The treatment could be administered in primary care centers to people who test positive for COVID-19, avoiding hospitalization due to the progression of the disease and complementing the vaccine in the early phase after vaccination. 18, 2021 /PRNewswire/ — Grifols (MCE: GRF, MCE: GRF.P, BARCELONA, Spain , Jan.

Clinical Trials 52

Clinical Trials Treatment Trials Hospitals 52

The Pharma Data

APRIL 7, 2021

today announced new data from its expansive neuroscience portfolio will be presented at the 2021 American Academy of Neurology (AAN) Annual Meeting, to be held virtually from April 17-22. . Key AbbVie abstracts and presentation details for the 2021 AAN Annual Meeting program are outlined below. Clinical Trials Plenary Session.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

Drug Discovery World

APRIL 25, 2023

University of California researchers have dosed the second participant in their clinical trial to identify a potential cure for HIV utilising CAR-T cell therapy. The trial is the first-in-human clinical study investigating the duo CAR-T cell therapy for the treatment of HIV. “We In 2021 there were an estimated 1.5

Research 130

Research Clinical Trials Therapies Clinical Development 130

Drug Discovery World

JULY 11, 2023

We are confident that the strong collaboration of the experienced teams at Evotec and BMS will make novel innovative treatment options available to patients living with a broad range of neurodegenerative conditions.” Evotec and BMS aim to identify disease-modifying treatments for a broad range of neurodegenerative diseases.

Licensing 189

Licensing Licensing Drugs Disease 189

The Pharma Data

JANUARY 12, 2021

The two-year, Phase 2 clinical trial included 272 patients with mild to moderate Alzheimer’s symptoms. After six to 12 months of treatment with the drug, patients no longer had amyloid protein plaques that are hallmarks of Alzheimer’s disease, according to Dr. The effect was seen on brain scans. © 2021 HealthDay.

Clinical Trials 52

Clinical Trials Laboratories Trials Treatment 52

Drug Target Review

JULY 4, 2023

These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. ADCs have the potential to redress the poor balance between safety and efficacy seen with traditional cancer treatment options. 3D rendering of Antibody Drug Conjugate Molecules.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

Drug Discovery World

AUGUST 21, 2023

Semaglutide manufacturer Novo Nordisk reported earlier this month that the drug reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity, as shown in the SELECT trial. The drugs are currently approved as treatments for type 2 diabetes and weight loss.

Clinical Trials 130

Clinical Trials Trials Treatment Licensing 130

The Pharma Data

JULY 29, 2021

Second-Quarter 2021 Revenues of $19.0 Billion The 10% Operational Growth Excluding BNT162b2(1) in Second-Quarter 2021 Builds on the 6% Operational Growth Delivered by the Comparable Business in Second-Quarter 2020 Second-Quarter 2021 Reported Diluted EPS(2) of $0.98, Adjusted Diluted EPS(3) of $1.07

Biosimilars 52

Biosimilars Vaccine International Production 52

The Pharma Data

JUNE 18, 2021

1 The full, long-term results from the Phase 3 SELECT-PsA 2 clinical trial will be presented at the EULAR 2021 Virtual Congress. 1 The full, long-term results from the Phase 3 SELECT-PsA 2 clinical trial will be presented at the EULAR 2021 Virtual Congress. Efficacy data reported based on randomized treatment.

Treatment 40

Treatment Therapies Clinical Trials Disease 40

The Pharma Data

DECEMBER 1, 2020

02, 2020 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today released its 2021 financial calendar: March 18, 2021: Publication of 2020 financial statements. MARSEILLE, France, Dec. . .

Cell Biology 52

Cell Biology Clinical Trials Licensing Licensing 52

The Pharma Data

JANUARY 3, 2021

. United Kingdom Medicines and Healthcare Products Regulatory Agency authorized Clinical Trial Application. 04, 2021 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. The Company expects to enroll the first subject in the first half of 2021 and provide preliminary safety and biomarker data in the second half of 2021.

Clinical Trials 52

Clinical Trials Trials Treatment FDA 52

The Pharma Data

MARCH 11, 2021

Eli Lilly and Company (NYSE: LLY) today announced that data from programs across its oncology portfolio and pipeline will be presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, to be held virtually April 10-15, 2021. LY3484356, an oral SERD, is currently being studied in a Phase 1/2 clinical trial.

Research 52

Research Clinical Trials FDA Approval Trials 52

The Pharma Data

AUGUST 3, 2021

today announced financial results for the second quarter of 2021. 2021 total revenues guidance reaffirmed at $25.8-$26.6 COVID-19 update : Compared to the first quarter of 2021, we have seen gradual recovery from the impacts of the COVID-19 pandemic. Key results include: Total revenues increased 5% to $6.5 on a non-GAAP basis.

Biosimilars 52

Biosimilars Production Treatment FDA 52

The Pharma Data

AUGUST 3, 2021

Breakthrough results in the treatment of a type of heart failure, which is extremely difficult to manage Strong progress in mental health pipeline Good business performance in all areas, despite ongoing impact of COVID-19. Our strong R&D pipeline has made further, decisive progress in the first half of 2021.

Research 52

Research Clinical Trials Treatment Production 52

The Pharma Data

NOVEMBER 23, 2021

Roche moment blazoned that new data from its expansive haematology portfolio will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition from 11-14 December 2021. 2 FL is the most common idle ( slow growing) form ofnon-Hodgkin carcinoma, a type of blood cancer, which frequently returns after original remedy.4

Treatment 52

Treatment Trials Drugs Production 52

The Pharma Data

MARCH 9, 2021

New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY) at the upcoming virtual International Conference on Alzheimer’s & Parkinson Diseases 2021 (AD/PD 2021), March 9-14, 2021. vice president of Alzheimer’s disease development unit, Eli Lilly and Company.

Disease 40

Disease International Research Therapies 40

The Pharma Data

MARCH 20, 2021

Precision imaging analytics technology known as radiomics will see increased adoption in 2021 and will be incorporated into drug development strategies and clinical trials management, according to Rose Higgins, CEO of HealthMyne. Source link: [link].

Clinical Trials 52

Clinical Trials Drug Development Trials Drugs 52

The Pharma Data

FEBRUARY 8, 2021

PARIS – February 5, 2021 – Today, Sanofi holds a virtual investor event with key members of the Sanofi leadership team to share and discuss the overall progress in implementing the strategy in core parts of the business as well as the transformation of R&D. Key highlights to be presented at Capital Markets Day 2021.

Marketing 52

Marketing Clinical Trials Disease Vaccine 52